Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:The primary objectives are: to assess the overall efficacy of PDE5 compared to placebo; to compare the efficacy of PDE5 to the existing medical treatments (α1-blockers and 5ARI); to compare the relative efficacy of PDE5 alone and in combination of PDE5 with other existing treatments in people with LUTS consistent with BPH. The secondary objectives are: to assess the efficacy of PDE5 on BPH-LUTS used at different doses; to compare the efficacy of PDE5 in patients with ED versus those who do not have ED; to evaluate the effect of PDE5 on LUTS in patients who had previously been treated with α1-blockers versus treatment naive patients; to analyse the long term efficacy of PDE5 on LUTS; to assess the safety of PDE5 in the short term (used at least for 4 weeks) as well as long term (used at least for 1 year).